Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to reduce the price of insulin and provide for patient protections with respect to the cost of insulin, S.4974, to amend the Federal Food, Drug, and Cosmetic Act with respect to food safety, S.5026, to require warning labels on sugar-sweetened foods and beverages, foods and beverages containing high-intensity sweeteners, ultra-processed foods, and foods high in nutrients of concern, such as added sugar, saturated fat, or sodium, to restrict junk food advertising to children, S.1414, to amend the Public Health Service Act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy, S.3788, to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information, S.3794, to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, S.494, to establish a national plan to coordinate research on epilepsy, S.4110, to revise and extend health workforce programs under title VII of the Public Health Service Act, S.1874, to amend the Public Health Service Act to reauthorize certain nursing workforce development programs, and S.380, to improve obstetric emergency care.

Open Business Meeting Wednesday, July 22, 2026 · 10:00 AM EDT Dirksen Senate Office Building, Room 430